Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta‐analysis

Abstract

Our meta-analysis supports that VEGF overexpression is an available poor predictor for patients with head and neck cancer.

VEGF expression in pancreatic cancer and other malignancies: a review of the literature

“…Thus, overexpression of VEGF was found in head and neck cancer [23,24]. By inducing proliferation of lymphatic endothelia cell and development of lymphatic vessels, VEGF-C and VEGF-D contributed to lymphatic metastasis of papillary thyroid carcinoma [25].…”

Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy

“…For instance, a recent meta-analysis on 6.781 patients confirmed the negative impact of epidermal growth factor receptor (EGFR) overexpression, especially in laryngeal squamous cell carcinoma [30]. Similar negative prognostic impact was shown for vascular endothelial growth factor (VEGF) overexpression [31]. These are just some examples of the most recent discoveries for H&N cancer patients.…”

Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck

“…Curiously, these findings are, on the whole, at odds with those drawn from two previous meta‐analyses examining VEGF expression in head and neck cancers . A recent 2013 meta‐analysis of 47 original studies reporting a total of 3476 tumor samples concluded that VEGF overexpression predicts poorer survival and greater risk of lymph node metastasis, whereas an earlier 2005 meta‐analysis demonstrated an association with poorer 2‐year survival, although not with risk of nodal metastasis .…”